Cargando…

Palliative Resection of Metastatic Brain Tumors Previously Treated by Stereotactic Radiosurgery

BACKGROUND: Therapeutic approaches to brain metastases include surgery, whole-brain radiotherapy, stereotactic radiosurgery (SRS), and combination therapy. Recently, postoperative or preoperative SRS draws more attention to reduce postoperative recurrence in brain metastases. The goal of this study...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeon, Yoo Sung, Koh, Young-Cho, Song, Sang Woo, Cho, Joon, Lim, So Dug
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Brain Tumor Society; The Korean Society for Neuro-Oncology; The Korean Society for Pediatric Neuro-Oncology 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5114182/
https://www.ncbi.nlm.nih.gov/pubmed/27867922
http://dx.doi.org/10.14791/btrt.2016.4.2.116
_version_ 1782468300415959040
author Jeon, Yoo Sung
Koh, Young-Cho
Song, Sang Woo
Cho, Joon
Lim, So Dug
author_facet Jeon, Yoo Sung
Koh, Young-Cho
Song, Sang Woo
Cho, Joon
Lim, So Dug
author_sort Jeon, Yoo Sung
collection PubMed
description BACKGROUND: Therapeutic approaches to brain metastases include surgery, whole-brain radiotherapy, stereotactic radiosurgery (SRS), and combination therapy. Recently, postoperative or preoperative SRS draws more attention to reduce postoperative recurrence in brain metastases. The goal of this study is to review surgical outcome of patients who had been treated by SRS, and to discuss the effectiveness of preoperative SRS. METHODS: From 2009 to 2015, 174 patients were treated by SRS for brain metastases, and among these 50 patients underwent surgery. Eighteen patients underwent surgery after SRS, and 14 had oligometastases. The patients' median age at the time of surgery was 56 years (range, 34–84 years). The median follow-up duration was 16.5 months (range, 4–47 months). Pathological findings were classified as follows; radiation necrosis (Group I, n=3), mixed type (Group II, n=2), and tumor-dominant group (Group III, n=9). We compared surgical outcome in respect of steroid, mannitol dosage, Karnofsky performance scale, and pathological subgroups. RESULTS: The median overall survival was 11 months (range, 2–40 months). Six, 12 and 24 months survival rate was 64.3, 42.9, and 28.6%, respectively. Improvement of Karnofsky performance score was achieved in 50% after surgery. The overall survival of Group I (26.6 months) was longer than the other groups (11.5 months). Additionally the patients were able to be weaned from medications, such as steroid administration after surgery was reduced in 10 cases, and mannitol dosage was reduced in 6 cases. Time interval within 3 months between SRS and surgery seemed to be related with better local control. CONCLUSION: Surgical resection after radiologically and symptomatically progressed brain metastases previously treated with SRS seems to be effective in rapid symptom relief and provides an improvement in the quality of life. A short time interval between SRS and surgical resection seems to be associated with good local tumor control.
format Online
Article
Text
id pubmed-5114182
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher The Korean Brain Tumor Society; The Korean Society for Neuro-Oncology; The Korean Society for Pediatric Neuro-Oncology
record_format MEDLINE/PubMed
spelling pubmed-51141822016-11-19 Palliative Resection of Metastatic Brain Tumors Previously Treated by Stereotactic Radiosurgery Jeon, Yoo Sung Koh, Young-Cho Song, Sang Woo Cho, Joon Lim, So Dug Brain Tumor Res Treat Original Article BACKGROUND: Therapeutic approaches to brain metastases include surgery, whole-brain radiotherapy, stereotactic radiosurgery (SRS), and combination therapy. Recently, postoperative or preoperative SRS draws more attention to reduce postoperative recurrence in brain metastases. The goal of this study is to review surgical outcome of patients who had been treated by SRS, and to discuss the effectiveness of preoperative SRS. METHODS: From 2009 to 2015, 174 patients were treated by SRS for brain metastases, and among these 50 patients underwent surgery. Eighteen patients underwent surgery after SRS, and 14 had oligometastases. The patients' median age at the time of surgery was 56 years (range, 34–84 years). The median follow-up duration was 16.5 months (range, 4–47 months). Pathological findings were classified as follows; radiation necrosis (Group I, n=3), mixed type (Group II, n=2), and tumor-dominant group (Group III, n=9). We compared surgical outcome in respect of steroid, mannitol dosage, Karnofsky performance scale, and pathological subgroups. RESULTS: The median overall survival was 11 months (range, 2–40 months). Six, 12 and 24 months survival rate was 64.3, 42.9, and 28.6%, respectively. Improvement of Karnofsky performance score was achieved in 50% after surgery. The overall survival of Group I (26.6 months) was longer than the other groups (11.5 months). Additionally the patients were able to be weaned from medications, such as steroid administration after surgery was reduced in 10 cases, and mannitol dosage was reduced in 6 cases. Time interval within 3 months between SRS and surgery seemed to be related with better local control. CONCLUSION: Surgical resection after radiologically and symptomatically progressed brain metastases previously treated with SRS seems to be effective in rapid symptom relief and provides an improvement in the quality of life. A short time interval between SRS and surgical resection seems to be associated with good local tumor control. The Korean Brain Tumor Society; The Korean Society for Neuro-Oncology; The Korean Society for Pediatric Neuro-Oncology 2016-10 2016-10-31 /pmc/articles/PMC5114182/ /pubmed/27867922 http://dx.doi.org/10.14791/btrt.2016.4.2.116 Text en Copyright © 2016 The Korean Brain Tumor Society, The Korean Society for Neuro-Oncology, and The Korean Society for Pediatric Neuro-Oncology http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Jeon, Yoo Sung
Koh, Young-Cho
Song, Sang Woo
Cho, Joon
Lim, So Dug
Palliative Resection of Metastatic Brain Tumors Previously Treated by Stereotactic Radiosurgery
title Palliative Resection of Metastatic Brain Tumors Previously Treated by Stereotactic Radiosurgery
title_full Palliative Resection of Metastatic Brain Tumors Previously Treated by Stereotactic Radiosurgery
title_fullStr Palliative Resection of Metastatic Brain Tumors Previously Treated by Stereotactic Radiosurgery
title_full_unstemmed Palliative Resection of Metastatic Brain Tumors Previously Treated by Stereotactic Radiosurgery
title_short Palliative Resection of Metastatic Brain Tumors Previously Treated by Stereotactic Radiosurgery
title_sort palliative resection of metastatic brain tumors previously treated by stereotactic radiosurgery
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5114182/
https://www.ncbi.nlm.nih.gov/pubmed/27867922
http://dx.doi.org/10.14791/btrt.2016.4.2.116
work_keys_str_mv AT jeonyoosung palliativeresectionofmetastaticbraintumorspreviouslytreatedbystereotacticradiosurgery
AT kohyoungcho palliativeresectionofmetastaticbraintumorspreviouslytreatedbystereotacticradiosurgery
AT songsangwoo palliativeresectionofmetastaticbraintumorspreviouslytreatedbystereotacticradiosurgery
AT chojoon palliativeresectionofmetastaticbraintumorspreviouslytreatedbystereotacticradiosurgery
AT limsodug palliativeresectionofmetastaticbraintumorspreviouslytreatedbystereotacticradiosurgery